Intuitive Surgical, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David J. Rosa
- Full Time Employees
- 17,021
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1020 Kifer Road Sunnyvale CA United States of America 94086-5304
- IPO Date
- Jun 16, 2000
- CIK
- 0001035267
- Website
- intuitive.com
- Similar Companies
- Business
- Intuitive Surgical, Inc. develops, manufactures, and markets advanced robotic-assisted surgical systems designed to enhance the quality and access to minimally invasive care globally. Its core products include the da Vinci Surgical System, which enables surgeons to perform a wide range of complex surgical procedures across specialties such as general surgery, urology, gynecology, cardiothoracic, and head and neck surgery using minimally invasive techniques. The company also offers the Ion Endoluminal System, a robotic platform for diagnostic endoluminal procedures enabling minimally invasive lung biopsies through advanced imaging and navigation technology. Intuitive’s product suite includes stapling, energy, and core instrumentation compatible with its multi-port da Vinci systems, alongside progressive learning pathways that facilitate clinical adoption, and a comprehensive infrastructure of service and support including installation, maintenance, technical support, proactive system health monitoring, and integrated digital capabilities that provide hospitals with data-driven insights to optimize surgical performance. Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical operates globally, supporting hospitals and surgical teams across over 60 countries. In the last 1-2 years, the company has advanced the commercial launch of its da Vinci 5 Surgical System, receiving regulatory clearances from the US FDA and CE mark in 2024, with 2025 focused on scaling the adoption of this platform through enhanced hardware and software upgrades featuring increased computing power and digital capabilities. Intuitive reported significant growth in system placements and procedure volumes, with a 14% year-over-year increase in installed base and 17% procedural growth as of mid-2025. Strategic priorities include expanding its robotic surgery ecosystem, reinforcing its recurring revenue model—which accounted for 84% of revenue in 2024—and furthering its Quintuple Aim framework aimed at improving patient outcomes, care team experience, access to care, and lowering total costs. Additionally, leadership transitioned in mid-2025 with President Dave Rosa promoted to CEO, signaling a new phase of growth and innovation focus. Despite rising competition in the robotic surgery field, Intuitive remains a dominant market leader through continuous technological innovation and strategic expansion. This comprehensive offering positions Intuitive Surgical as a pioneer and global leader in robotic-assisted, minimally invasive surgical technology, serving healthcare providers with products, services, and digital innovations that collectively enhance surgical precision, patient recovery, and overall healthcare system efficiency.
Breakfast News: Week in Review
Breakfast News: BBB Foods Opens Shops at Full Tilt
ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?
Intuitive Surgical: Priced For Precision
This Intuitive Surgical Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Intuitive Surgical (ISRG) Stock Has Plunged 33% in 2026. Here's Why One Fund Manager Remains Bullish -- and Why I Do, Too.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More
Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall
The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run
ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?
Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?
Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech
The Robotic Surgery Leader: Intuitive Surgical Slides Further But One Wall Street Bull Pegs Returns at 85%
Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
BankChampaign National Association Invests $908,000 in Intuitive Surgical, Inc. $ISRG
Is ISRG Winning the Next Phase of Robotic Surgery Beyond Urology?
This Stock Is Knocking on the Door of the Dividend Kings -- and Wall Street Thinks It Has Room to Run
Amundi Acquires 193,096 Shares of Intuitive Surgical, Inc. $ISRG
ISRG Q2 Earnings Call Signals Durable Demand & U.S. Caution